Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PV Stock Forecast 2025-2026
$1.94
Current Price
$80.32M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PV Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PV Price Momentum
-7.2%
1 Week Change
-10.2%
1 Month Change
+23.6%
1 Year Change
-3.5%
Year-to-Date Change
-27.9%
From 52W High of $2.69
+47.0%
From 52W Low of $1.32
📊 TOP ANALYST CALLS
Did PV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Primavera Capital is one of their latest high-conviction picks.
Latest PV Stock Price Targets & Analyst Predictions
PV has shown a year-to-date change of -3.5% and a 1-year change of 23.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PV. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PV Analyst Ratings
0
Buy
0
Hold
0
Sell
PV Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.94
Latest PV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Primavera Capital Acquisition Corporation (PV) Competitors
The following stocks are similar to Primavera Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Primavera Capital Acquisition Corporation (PV) Financial Data
Valuation Metrics
Market Cap
$80.32M
Enterprise Value
$0
P/E Ratio
30.0x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.2%
Current Ratio
0.5x
Debt/Equity
0.0x
ROE
+5.5%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Primavera Capital Acquisition Corporation (PV) Business Model
About Primavera Capital Acquisition Corporation
What They Do
N/A
Business Model
N/A
Additional Information
N/A
Company Information
Primavera Capital Acquisition Corporation (PV) Latest News & Analysis
Latest News
Quick Summary
PharmaEssentia USA's BESREMi® is now included in the latest NCCN Guidelines (Version 1.2025) as a recommended treatment option, enhancing its market position in hematology and oncology.
Why It Matters
The NCCN's endorsement of BESREMi® for treatment boosts PharmaEssentia's credibility and market potential, likely influencing stock performance and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia announced positive topline results from its SURPASS-ET trial for ropeginterferon alfa-2b-njft, achieving the primary endpoint with durable responses in essential thrombocythemia patients.
Why It Matters
Positive trial results for PharmaEssentia's P1101 could lead to increased market confidence and potential revenue growth, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia has signed an exclusive licensing agreement with FORUS Therapeutics for the registration and distribution of BESREMi® in Canada, aimed at treating polycythemia vera.
Why It Matters
The licensing agreement expands PharmaEssentia's market reach in Canada for BESREMi®, potentially increasing revenue and enhancing its position in the hematology and oncology sectors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Germany's grid-connected battery storage capacity could reach 60 GW by 2050, a fortyfold increase, driven by cost reductions and faster installations, similar to photovoltaics.
Why It Matters
The rapid growth in battery storage capacity signals a shift in energy supply dynamics, potentially impacting energy stocks, investment strategies, and future market trends.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA announced results from a real-world data review published for the ASCO Annual Meeting, highlighting its focus on hematology and oncology biologics.
Why It Matters
PharmaEssentia's new data review could enhance its credibility and market position in hematology and oncology, potentially impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA published an article in the British Journal of Clinical Pharmacology on the treatment of polycythemia with ropeginterferon alfa-2b, highlighting its efficacy and safety.
Why It Matters
The publication signifies potential advancements in treatment efficacy and safety for patients, which could enhance PharmaEssentia's market position and drive stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PV Stock
What is Primavera Capital Acquisition Corporation's (PV) stock forecast for 2026?
Analyst forecasts for Primavera Capital Acquisition Corporation (PV) are not currently available. The stock is trading at $1.94.
Is PV stock a good investment in 2026?
Analyst ratings for PV are not currently available. The stock is currently trading at $1.94. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PV stock?
Price predictions from Wall Street analysts for PV are not currently available. The stock is trading at $1.94.
What is Primavera Capital Acquisition Corporation's business model?
N/A
What is the highest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $1.94.
What is the lowest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $1.94.
What is the overall PV consensus from analysts for Primavera Capital Acquisition Corporation?
Analyst ratings for PV are not currently available. The stock is trading at $1.94.
How accurate are PV stock price projections?
Stock price projections, including those for Primavera Capital Acquisition Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 8, 2025 4:19 PM UTC